1 active not recruiting, 1 completed, 1 unknown. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Abemaciclib, Abiraterone, Prednisone or Prednisolone - Prostatic Neoplasms, Neoplasm Metastasis | Phase 3 | Active not recruiting | Eli Lilly and Company | 925 | 2022-04-14 | 2026-07-01 |
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer. Palonosetron, Ondansetron - Breast Neoplasm, Antineoplastic Agents | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cancerologia de Mexico | 560 | 2015-11-05 | 2018-07-30 |
| Erbitux MEtastatic Colorectal Cancer Strategy Study Cetuximab, FOLFIRI - Antineoplastic Agents | Phase 3 | Completed | Armando Orlandi | 607 | 2015-02-01 | 2020-03-31 |
Breast Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Urogenital Neoplasms (1)
Neoplasms (3) · Neoplasms by Site (3) · Breast Diseases (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1)
Cetuximab (1) · IFL protocol (1) · Ondansetron (1) · Palonosetron (1) · Prednisolone (1) · Prednisone (1) · abemaciclib (1) · abiraterone (1)
Armando Orlandi (1) · Eli Lilly and Company (1) · Instituto Nacional de Cancerologia de Mexico (1)
Italy (2) · Mexico (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Japan (1)
Claudia H Arce Salinas, MD (1)
PMID 11226762, PMID 12686700, PMID 12697943, PMID 1352024, PMID 15139073, PMID 16766588, PMID 17187507, PMID 17530482, PMID 18525044, PMID 19037667, PMID 20972805, PMID 21533811, PMID 22488022, PMID 23358260, PMID 24761161, PMID 25012726, PMID 25106522, PMID 3281702, PMID 3544842, PMID 38181312, PMID 6681766, PMID 9789602
2014 (1)